{
  "id": "5e48b7e2d14c9f295d000014",
  "type": "summary",
  "question": "What is the use of erenumab?",
  "ideal_answer": "Erenumab is a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in migraine frequency in phase II and III clinical trials. Based on these positive results erenumab was recently approved in the US for the preventive treatment of migraine in adults and has received a positive opinion in the EU for the prophylaxis of migraines in adults who have at least 4 migraine days per month.\n\nConclusions As a preventive treatment of episodic migraine, erenumab at a dosage of 70 mg monthly significantly reduced migraine frequency and acute migraine-specific medication use.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
    "http://www.ncbi.nlm.nih.gov/pubmed/31612482",
    "http://www.ncbi.nlm.nih.gov/pubmed/31284729",
    "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
    "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
    "http://www.ncbi.nlm.nih.gov/pubmed/30276500",
    "http://www.ncbi.nlm.nih.gov/pubmed/30963506",
    "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
    "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
    "http://www.ncbi.nlm.nih.gov/pubmed/29571276",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
    "http://www.ncbi.nlm.nih.gov/pubmed/29406534",
    "http://www.ncbi.nlm.nih.gov/pubmed/29263689",
    "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
    "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
    "http://www.ncbi.nlm.nih.gov/pubmed/30142988",
    "http://www.ncbi.nlm.nih.gov/pubmed/30235976",
    "http://www.ncbi.nlm.nih.gov/pubmed/30813769",
    "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
    "http://www.ncbi.nlm.nih.gov/pubmed/30614741"
  ],
  "snippets": [
    {
      "text": "Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Erenumab was generally well tolerated, with an acceptable safety profile, supporting further clinical development of erenumab for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions As a preventive treatment of episodic migraine, erenumab at a dosage of 70\u2009mg monthly significantly reduced migraine frequency and acute migraine-specific medication use. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571276",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION: Erenumab is predicted to reduce migraine-related direct and indirect costs, and increase QALYs compared to SC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571276",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Amgen and Novartis are developing erenumab (AIMOVIG\u2122, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in migraine frequency in phase II and III clinical trials. Based on these positive results erenumab was recently approved in the US for the preventive treatment of migraine in adults and has received a positive opinion in the EU for the prophylaxis of migraines in adults who have at least 4 migraine days per month. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a new preventive treatment for migraines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30813769",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab for episodic migraine prophylaxis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30614741",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Erenumab is a fully human monoclonal antibody (mAb), which specifically blocks the calcitonin gene-related peptide (GGRP) receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30614741",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Controlled Trial of Erenumab for Episodic Migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Conclusion:  Erenumab is an effective once-monthly injectable agent for migraine prevention in patients with chronic or episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30813769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion The use of erenumab may be a cost-effective approach to preventing monthly migraine days among patients with chronic migraine versus onabotulinumtoxinA and no preventive treatment in the societal and payer perspectives, but is less likely to offer good value for money for those with episodic migraine, unless lost productivity costs are considered.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30142988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nErenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over a period of 6 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nErenumab is an efficacious and well tolerated preventive treatment in adult patients with episodic and chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30142988",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Erenumab is a new preventive treatment for migraines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab in the treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30235976",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Conclusion The use of erenumab may be a cost-effective approach to preventing monthly migraine days among patients with chronic migraine versus onabotulinumtoxinA and no preventive treatment in the societal and payer perspectives , but is less likely to offer good value for money for those with episodic migraine , unless lost productivity costs are considered",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30142988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29263689",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Based on these positive results erenumab was recently approved in the US for the preventive treatment of migraine in adults and has received a positive opinion in the EU for the prophylaxis of migraines in adults who have at least 4 migraine days per month",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erratum: Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [ Corrigendum",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29406534",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a new preventive treatment for migraines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE\nTo evaluate the efficacy and safety of erenumab as preventive treatment in patients with migraine using meta-analytical techniques.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29263689",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Conclusion The use of erenumab may be a cost-effective approach to preventing monthly migraine days among patients with chronic migraine versus onabotulinumtoxinA and no preventive treatment in the societal and payer perspectives, but is less likely to offer good value for money for those with episodic migraine, unless lost productivity costs are considered.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30142988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Erenumab is a human anti-calcitonin gene-related peptide monoclonal antibody developed for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30963506",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in migraine frequency in phase II and III clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results With an annual drug price of erenumab of $6900, treatment with erenumab in the societal perspective ranges from a dominant strategy versus no preventive treatment among chronic migraine patients to an incremental cost-effectiveness ratio of $122,167 versus no preventive treatment among episodic migraine patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30142988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Monthly subcutaneous injections of erenumab 70\u00a0mg demonstrated statistically significant and numerically maximal efficacy with a favorable safety profile, suggesting that erenumab is a potential new therapy for migraine prevention in Japan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31612482",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PCONCLUSIONS: Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over a period of 6 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a human CGRP-receptor antibody approved for the prophylactic treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31284729",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early onset of efficacy with erenumab in patients with episodic and chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30276500",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a\u2009\u2265\u200950% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30276500",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a new preventive treatment for migraines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate the differences in costs and outcomes of the preventive treatment with erenumab versus onabotulinumtoxinA in patients with chronic migraines (CM) in Greece to assess the economic value of this treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31302899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over a period of 6 months.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Erenumab is an effective once-monthly injectable agent for migraine prevention in patients with chronic or episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30813769",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30793254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a human anti-calcitonin gene-related peptide monoclonal antibody developed for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30963506",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}